The drugs industry closed the day up 2%. Telik Inc ( TELK), Cormedix Inc ( CRMD), Sangamo BioSciences Inc ( SGMO), and ProPhase Labs Inc ( PRPH) were all decliners today within the drugs industry with Exact Sciences Corporation ( EXAS) being today's featured drugs loser. Exact Sciences Corporation fell 17 cents (-2.4%) to $7.14 on light volume. Throughout the day, 434,684 shares of Exact Sciences Corporation exchanged hands as compared to its average daily volume of 734,900 shares.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing a molecular diagnostic screening technology for the early detection and prevention of colorectal pre-cancer and cancer. Exact Sciences Corporation has a market cap of $351.1 million and is part of the health care sector. Shares are up 16.6% year to date as of the close of trading on Wednesday.

TheStreet Ratings rates Exact Sciences as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

On the positive front, Tibet Pharmaceuticals Inc ( TBET), NovaBay Pharmaceuticals Inc ( NBY), Neptune Technologies & Bioressources Inc ( NEPT), and Inovio Pharmaceuticals Inc ( INO) were all gainers within the drugs industry with AstraZeneca ( AZN) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Exact Sciences Stock Falls on Secondary Stock Sale

Exact Sciences: Cramer's Top Takeaways

Profits Trump Economic Weakness: Cramer's 'Mad Money' Recap (Friday 6/2/17)